Yao Y - Search Results

1

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.

Qi WX, Tang LN, He AN, Shen Z, Yao Y. Qi WX, et al. Among authors: yao y. Lung. 2011 Dec;189(6):437-43. doi: 10.1007/s00408-011-9332-1. Epub 2011 Oct 11. Lung. 2011. PMID: 21986852

2

Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.

Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC, Tang LN, Zhang W. Yao Y, et al. Chin Med J (Engl). 2006 Nov 5;119(21):1829-33. Chin Med J (Engl). 2006. PMID: 17097039 No abstract available.

3

The expression of CRM1 is associated with prognosis in human osteosarcoma.

Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE. Yao Y, et al. Oncol Rep. 2009 Jan;21(1):229-35. Oncol Rep. 2009. PMID: 19082467

4

Down-regulation of ribosomal protein L7A in human osteosarcoma.

Zheng SE, Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Sun YJ, Tang LN. Zheng SE, et al. Among authors: yao y. J Cancer Res Clin Oncol. 2009 Aug;135(8):1025-31. doi: 10.1007/s00432-008-0538-4. Epub 2009 Jan 6. J Cancer Res Clin Oncol. 2009. PMID: 19125294

5

Co-expression of ER-beta and HER2 associated with poorer prognosis in primary breast cancer.

Qui WS, Yue L, Ding AP, Sun J, Yao Y, Shen Z, Fan LH. Qui WS, et al. Among authors: yao y. Clin Invest Med. 2009 Jun 1;32(3):E250-60. doi: 10.25011/cim.v32i3.6114. Clin Invest Med. 2009. PMID: 19480740

6

Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.

Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H, Yao Y. Lin F, et al. Among authors: yao y. Med Oncol. 2011 Jun;28(2):649-53. doi: 10.1007/s12032-010-9493-4. Epub 2010 Mar 27. Med Oncol. 2011. PMID: 20349215

7

Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.

Qi WX, Shen Z, Yao Y. Qi WX, et al. Among authors: yao y. Cancer Chemother Pharmacol. 2012 Jan;69(1):99-106. doi: 10.1007/s00280-011-1678-9. Epub 2011 May 24. Cancer Chemother Pharmacol. 2012. PMID: 21607554

8

Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.

Qi WX, He AN, Tang LN, Shen Z, Yao Y. Qi WX, et al. Among authors: yao y. Med Oncol. 2012 Sep;29(3):2229-33. doi: 10.1007/s12032-011-0021-y. Epub 2011 Jul 7. Med Oncol. 2012. PMID: 21748427 Clinical Trial.

9

Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.

Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, Shen Z, Yao Y, Dong Y. Lin F, et al. Among authors: yao y. Asia Pac J Clin Oncol. 2011 Sep;7(3):270-5. doi: 10.1111/j.1743-7563.2011.01406.x. Asia Pac J Clin Oncol. 2011. PMID: 21884438

10

Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.

Qi WX, Shen Z, Yao Y. Qi WX, et al. Among authors: yao y. J Cancer Res Clin Oncol. 2011 Dec;137(12):1785-90. doi: 10.1007/s00432-011-1052-7. Epub 2011 Sep 14. J Cancer Res Clin Oncol. 2011. PMID: 21915752

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,666 results

Search Page

Filters